Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jun;47(6):2187-2196.
doi: 10.1007/s00261-022-03444-1. Epub 2022 Mar 21.

Prostate cancer in PI-RADS scores 1 and 2 version 2.1: a comparison to previous PI-RADS versions

Katja Bogner  1 , Karl Engelhard  2 , Wolfgang Wuest  2 , Sajad Hamel  2
Affiliations

Prostate cancer in PI-RADS scores 1 and 2 version 2.1: a comparison to previous PI-RADS versions

Katja Bogner et al. Abdom Radiol (NY). 2022 Jun.

Abstract

Purpose: To evaluate the validity of PI-RADS categories 1 and 2 version 2.1 (V2.1) as predictors of the absence of carcinoma and to reevaluate lesions that were analysed as suspicious prior to PI-RADS or according to PI-RADS versions 1 and 2 and classified as PI-RADS 1 or 2 in V2.1.

Methods: Retrospective evaluation of 1170 multiparametric MRIs performed at one academic teaching hospital (2012-2019). Study cohort comprised 188 men that achieved PI-RADS scores 1 or 2 (V2.1) and underwent systematic and targeted biopsy, split into one group with suspect findings in the original reports that were created prior to PI-RADS or with version 1 and 2, and another group with unremarkable reports. Differences in presence of prostate cancer and PSA density were assessed by Chi-square and Fisher's exact test, and the negative predictive value (NPV) for both groups was conducted.

Results: The NPV for clinically significant carcinoma (csCa) was 89.1% for 55 men with suspect findings in the original report and 93.2% for 133 men with negative MRI. There was no difference between the groups regarding the detection of csCa (p = 0.103). PSA density was significantly higher in the group with suspect original reports (p = 0.015).

Conclusion: A PI-RADS score 1 or 2 appears less likely to miss existing prostate cancer, although a small amount of csCa can be overlooked. In case of clinical suspicion or elevated PSA density and PI-RADS score 1 or 2, an individual decision has to be taken if biopsy is necessary or if monitoring is sufficient.

Keywords: Multiparametric magnetic resonance imaging; PI-RADS scores 1 and 2; PI-RADS versions; Prostatic neoplasms.

PubMed Disclaimer

References

    1. German Cancer Society, German Cancer Aid, AWMF (2021) S3-Leitlinie Prostatakarzinom, Langversion 6.0 [S3-guideline Prostate Carcinoma, long version 6.0]. http://www.leitlinienprogramm-onkologie.de/leitlinien/prostatakarzinom/ . Accessed 26 Jun 2021
    1. Mottet N, Bellmunt J, Bolla M et al. (2017) EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol 71:618–629. https://doi.org/10.1016/j.eururo.2016.08.003 - DOI - PubMed
    1. Barentsz JO, Richenberg J, Clements R et al. (2012) ESUR prostate MR guidelines 2012. Eur Radiol 22:746–757. https://doi.org/10.1007/s00330-011-2377-y - DOI - PubMed - PMC
    1. Weinreb JC, Barentsz JO, Choyke PL et al. (2016) PI-RADS Prostate Imaging - Reporting and Data System: 2015, Version 2. Eur Urol 69:16–40. https://doi.org/10.1016/j.eururo.2015.08.052 - DOI - PubMed
    1. Turkbey B, Rosenkrantz AB, Haider MA et al. (2019) Prostate Imaging Reporting and Data System Version 2.1: 2019 Update of Prostate Imaging Reporting and Data System Version 2. Eur Urol 76:340–351. https://doi.org/10.1016/j.eururo.2019.02.033 - DOI - PubMed

Substances

LinkOut - more resources